A non-inferiority trial of cytisine versus varenicline for smoking cessation.

金雀花碱与伐尼克兰戒烟的非劣效性试验。

• 批准号: nhmrc : GNT1108318
• 负责人: A/Pr Coral Gartner
• 金额: $ 188.58万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/non-inferiority-trial-smoking-cessation/1346640
• 关键词: non; inferiority; trial; cytisine; versus

Long-term quit rates via existing behavioural and pharmacological approaches to smoking cessation remain low and there is a need for further evidence-based treatments to complement standard treatment. We will conduct a large-scale trial to demonstrate the cost-effectiveness of cytisine compared to existing varenicline treatment. The findings will have direct health care system implications and cytisine, if effective, has the potential to save millions of lives globally.

通过现有的行为和药理学方法戒烟的长期戒烟率仍然很低，需要进一步的循证治疗来补充标准治疗。我们将进行一项大规模的试验，以证明金雀花碱与现有的伐尼克兰治疗相比的成本效益。这些发现将对医疗保健系统产生直接影响，金雀花碱如果有效，有可能挽救全球数百万人的生命。